

Parabolic Drugs Limited

Registered & Corporate Office: SCO. 99 - 100, Top Floor, Sector - 178, Chandigarh

Unaudited Financial Results for the Nine months Ended 31st December' 2014

							Rs. Crores)
S.no.	Particulars	Three months Ended 31.12.2014	Preceding three months ended 30.09,2014	Corresponding Three months Ended	Nine months Ended 31.12.2014	Corresponding nine months ended 31,12,2013 in	Previous Accounting Year ended 31.03.2014
		r		31.12.2013 in the previous year		the previous	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1			·	· ·	<u> </u>		-
[[Income from Operations	45.18	53.30	113.48	212.11	330.53	446.71
	Gross Sales Less: Excise Duty	(2.28)	(3.67)	(5.41)	(9.94)	(12.20)	(16.33)
	(a) Net Sales/Income from Operations (Net of			100.07	. 202,17	318.33	430.38
	excise duty)	42.9 <u>0</u> 0.92	** * 49.63 0.77	108.07 6.35	2.54	12.69	20.20
	(b)Other Operating Income Total Income from Operations (net)	43.82	50.40	114.42	204.71	331.02	450.58
.2	Expenses		· · · · · · · · · · · · · · · · · · ·			\ 	200.63
	(a) Cost of Materials Consumed (b) Changes in Inventories of finished goods,	31.99	39.77_	97.97	167.42	296.40	390.62
	(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	1.64	0.40	(0.54)	2.04	(20.73)	(21.40)
	(c) Employee Benefits Expense	4.69	3.92	5.02	13.28	14.02	18.55
		17.19	17.26	17.03	51.68	51.06	68.08
,	(d) Depreciation & Amortisation Expense (e) Other Expenses (Any Item exceeding 10%		17,.20	1			
	of the total expenses relating to continuing		40.00	10.41	28.27	33.11	131.68
	operations to be shown separately)	8.52 64.03	10.93 72.28	10.41 129.89	262.69	373.86	587.53
3	Total Expenses Profit/(Loss) from Operations before Other	04.03	7 2120	1			
4	Income, Finance Costs & Exceptional Items (1 - 2)	[20.21]	(21.88)	(15.47)	(57. <u>98</u>)	(42.84)	(136.95)
5	Other Income	· · · · · ·			-	+· - 	_
	Profit/(Loss) from ordinary activities before finance costs and exceptional items	٠.					
6	(3 + 4)	(20.21			(57 <u>.98</u> 55.80		(136.95) 83.07
7	Finance Costs	18.97	18.69	19.93		33.32	
8	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(39.18	(40.57)	(35.40)	(113.78	(102.36)	(220.02)
9	Exceptional Items	<u> </u>			<u> </u>	-	
io	Profit /(Loss) from Ordinary Activities before tax (7 + 8)	(39.18	(40.57)	(35.40)	(113.78	(102.36)	(220.02)
11	Tay expense		(12.53	(10.94)	(23.05) (31.63)	(61,30)
12	Net Profit/(Loss) from Ordinary Activities after tax (9 - 10)	(39.18	(28.04	(24.46)	(90.73) (70 <u>.73</u>)	(158.72) (26.98)
13	Extra Ordinary Items (net of tax expense)	/20.19	(28.04) (24.46)	(90.73	(70.73)	(131.74)
14_	Net Profit / (Loss) for the period (11-12) Share of Profit/(Loss) of Associates	(39.18	120.04	- (21.10)	-	,	
15 16	Minority Interest					-	-
17	Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of						
	Associates (13 +14 + 15)	(39.18	(28.04	(24.46	(90.73	(70.7 <u>3</u>)	(131.74)
18	Pald-up equity share capital (face Value of the Share shall be indicated) (Rs. 10/- each)	61.89	61.89	61.89	61.89	61.89	61.89
	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	·			<u> </u>	·	226.76
19 (1)	- Charles (Fort) (hafana automordinam)						
	annualised)	(6.33	3) (4.53	(3.95	(14.66	(11.43)	(21.29
<u> </u>	(a) Basic(b) Diluted	(6.3					(21.29
19 (ii	Earnings Per Share (EPS) (after extraordinary) items) -Shares of Rs. 10/- each (not						
	annualised)	(6.3)	3) (4.53	3) (3.95	(14.56	(11.43	(21.29
. [.	(a) Basic(b) Diluted	(6.3				• •	
Α.	PARTICULARS OF SHAREHOLDING	,,,,,,			T		
1	Public Shareholding :	L		1 20 20 20 20 20 20 20 20 20 20 20 20 20	37,974,587	38,362,317	3818293
	- Number of Shares	37,974,58	7 37,974,587	7 <u>38,362,317</u>	<u></u>	1 302,302,311	1 3010293







Parabolic Drugs Limited

Registered & Corporate Office: SCO. 99 - 100, Top Floor, Sector - 178, Chandigarh Unaudited Financial Results for the Nine months Ended 31st December' 2014

		٠.					(Rs. Crores)
S.no.	Particulars	Three months Ended 31.12.2014	Preceding three months ended 30.09.2014	Corresponding Three months Ended 31.12.2013 in the previous year	Nine months Ended 31.12,2014	Corresponding nine months ended 31.12.2013 in the previous year	Previous Accounting Year ended 31.03.2014
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
⊢–	- Percentage of Shareholding	61.36	51.36	61.98	61.36	61.98	61.69
2	Percentage or Snarenording			. —			
]	Promoters and Promoter Group Shareholding:			<u> </u>			
	(a) Piedged/Encumbered	<u> </u>	<u></u>	<u>-</u>	<u>-</u> _		
	- Number of shares	22,619,927	22,619,927_	22,217,497	22,619,927	22,217,497	22372320
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	94.58	94.58	94.42	94.58	94.42	94.36
	- Percentage of shares (as a % of the total share capital of the company)	36.55	36.55	35.90	36.55	35.90	36.14
	(b) Non-Encumbered		<u> </u>	ļ 			1006750
	- Number of shares	1,297,500	1,297,500	1,312,200	1,297,500	1,312,200	1336759
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	5.42	5,42	5.58	5.42	5.58	5.64
L. <u> </u>	- Percentage of shares (as a % of the total share capital of the company)	2.10	2.10	2.12	2.10	2.12	2.16
В.	INVESTOR COMPLAINTS					Quarter ended 31/12/2014	Quarter ended 31/12/2013
ì	Pending at the beginning of the quarter					Nil	Nii
	Received during the quarter		·			Nil	1
	Disposed of during the quarter					NII	1
	Remaining unresolved at the end of the quarter					Nil	Nil

Notes :

- 1. The above quarterly results have been reviewed by the Audit Committee and taken on record by the Board of Directors in their meeting held on 14th February, 2015 and the same have been reviewed by the Statutory Auditors, as required under Clause 41 of the Listing Agreement.
- 2. During the period under review, the company has incurred loss owing to the unfavourable market conditions, interest burden and economic stress, the company has witnessed an erosion in the margins of key products.
- 3. The promoters' shareholding has been pledged pursuant to the terms of CDR package.
- 4. There is not more than one reportable segment, hence, information as per AS-17 is not required to be be disclosed.
- 5. Figures of the previous year / period have been rearranged/regrouped wherever necessary.

Place: Chandigarh Date:14th Feb., 2015 For Parabolic Drugs Ltd.

Pranav Gupta
Chairman & Managing Director